BNT116 + cemiplimab + carboplatin + paclitaxel

BNT116 + cemiplimab + carboplatin + paclitaxel is an investigational **combination therapy** being evaluated for **non-small cell lung cancer (NSCLC)**. - **BNT116** is an mRNA-based cancer vaccine developed by BioNTech. It encodes selected tumor antigens associated with NSCLC, aiming to prime the immune system—especially cytotoxic T cells—to recognize and destroy cancer cells expressing these targets, thus providing a targeted immunotherapy approach[1][3][5][7]. - **Cemiplimab** is a fully human monoclonal antibody (PD-1 inhibitor) that blocks the programmed cell death-1 (PD-1) checkpoint, enhancing T-cell mediated antitumor responses. - **Carboplatin** is a platinum-based chemotherapy agent that exerts cytotoxic effects on rapidly dividing cancer cells by inducing DNA crosslinks, leading to apoptosis[2][4][6][8]. - **Paclitaxel** is a microtubule-stabilizing chemotherapeutic agent that inhibits cell division, leading to cancer cell death[2][4][6][8]. The rationale for this combination is to combine a tumor-specific immune primer (BNT116), immune checkpoint inhibition (cemiplimab), and standard cytotoxic chemotherapy to maximize immune activation and tumor killing in NSCLC. Clinical studies are evaluating safety, tolerability, and preliminary efficacy in advanced and resectable NSCLC across multiple phases and settings[1][3][5][7].

Brand names

paclitaxel does not have a unique brand name as part of this combination

Other names

BNT116 + cemiplimab + carboplatin + paclitaxel